# Oral OKT3 in Combination With Beta-D-Glucosylceramide

> **NCT00619372** · PHASE1 · UNKNOWN · sponsor: **Hadassah Medical Organization** · enrollment: 20 (estimated)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** OKT3
- **DRUG:** OKT3, GC
- **DRUG:** OKT3
- **DRUG:** OKT3, GC
- **DRUG:** OKT3
- **DRUG:** GC

## Key facts

- **NCT ID:** NCT00619372
- **Lead sponsor:** Hadassah Medical Organization
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-01
- **Primary completion:** 2008-04
- **Final completion:** 2008-06
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2009-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00619372

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00619372, "Oral OKT3 in Combination With Beta-D-Glucosylceramide". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00619372. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*